Toshiba American Systems Inc. today announced FDA clearance of their M-Power interface aimed at increasing MR exam efficiency. The customizable user interface enables technologists to streamline and accelerate the imaging process and enhance diagnosis, according to the company.
Toshiba American Systems Inc. today announced FDA clearance of their M-Power interface aimed at increasing MR exam efficiency. The customizable user interface enables technologists to streamline and accelerate the imaging process and enhance diagnosis, according to the company.
M-Power will be available for use on Toshiba’s Vantage Atlas, Vantage Titan 1.5 and Titan 3T MR systems with the ability to upgrade already-installed systems.
M-Power reduces the steps to start a procedure, and the interface is designed to enhance and personalize work flow. The Atlas Compass software automates coil selection and turns on the proper coil elements needed for an exam. Finally, mVOX, a volume imaging acquisition sequence available for neuro and orthopedic applications, allows the acquisition of all 3D imaging to be acquired at the same time, according to the company.
“M-Power makes Toshiba’s sophisticated suite of MR software easy to learn and use, allowing technologists of every skill level to access the system’s full range of functionality,” Stuart Clarkson, director, MR Business Unit, Toshiba, said in the company release. “MR technologists are now able to design their own protocols and easily access mTools for greater convenience and productivity.”
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which will be unveiled at the American College of Cardiology (ACC) conference.